Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Circulation ; 104(25): 3145-51, 2001 Dec 18.
Artigo em Inglês | MEDLINE | ID: mdl-11748115

RESUMO

BACKGROUND: Interleukin (IL)-12 exerts a potent proinflammatory effect by stimulating T-helper (Th) 1 responses. This effect is believed to be mediated primarily through the activation of STAT4 and subsequent production of interferon (IFN)-gamma. Methods and Results- We examined the role of IL-12 receptor (IL-12R) signaling in the development of murine experimental autoimmune myocarditis (EAM) induced by cardiac myosin immunization. Both IL-12Rbeta1-deficient mice and STAT4-deficient mice were resistant to the induction of myocarditis. Treatment with exogenous IL-12 exacerbated disease. We questioned whether IFN-gamma is required for the disease-promoting activity of IL-12. On the contrary, we found that IFN-gamma suppresses EAM. Lack of IFN-gamma due to either depletion with an antibody or a genetic deficiency exacerbated myocarditis. Spleens from IFN-gamma-deficient mice immunized with cardiac myosin showed increased cellularity; greater numbers of CD3+, CD4+, CD8+, and IL-2-producing cells; and heightened ability to produce cytokines on stimulation in vitro. Treatment of mice with recombinant IFN-gamma suppressed the development of myocarditis. CONCLUSIONS: IL-12/IL-12R/STAT4 signaling promotes the development of EAM. In contrast, IFN-gamma plays a protective role. The disease-limiting effects of IFN-gamma might be explained by its ability to control the expansion of activated T lymphocytes.


Assuntos
Doenças Autoimunes/fisiopatologia , Proteínas de Ligação a DNA/fisiologia , Interferon gama/fisiologia , Miocardite/fisiopatologia , Receptores de Interleucina/fisiologia , Transativadores/fisiologia , Animais , Doenças Autoimunes/patologia , Doenças Autoimunes/prevenção & controle , Complexo CD3/análise , Antígenos CD4/análise , Antígenos CD8/análise , Células Cultivadas , Citocinas/efeitos dos fármacos , Citocinas/metabolismo , Proteínas de Ligação a DNA/genética , Feminino , Citometria de Fluxo , Genótipo , Interferon gama/genética , Interferon gama/farmacologia , Interleucina-12/farmacologia , Camundongos , Camundongos Endogâmicos BALB C , Camundongos Knockout , Miocardite/patologia , Miocardite/prevenção & controle , Miocárdio/imunologia , Miocárdio/patologia , Miosinas/imunologia , Receptores de Interleucina/genética , Receptores de Interleucina-12 , Fator de Transcrição STAT4 , Transdução de Sinais , Baço/citologia , Baço/efeitos dos fármacos , Baço/metabolismo , Linfócitos T/citologia , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Transativadores/genética
2.
Medicine (Baltimore) ; 78(6): 370-81, 1999 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-10575419

RESUMO

We investigated the presence of hypergammaglobulinemia and oligo-/monoclonal gammopathy in 90 patients (from 80 families) with ataxia-telangiectasia ranging in age from 2 to 29 years. Of the 90 patients, 38.8% displayed hypergammaglobulinemia. An isolated increase in IgM was the most common finding (23.3%) followed by a simultaneous increase in IgM and IgG (8.8%), an isolated increase in IgA (3.3%), an elevated level of IgG (2.2%) and a concomitant increase in IgM and IgA (1.1%), respectively. Seven of the patients (8.1%) had oligo-/monoclonal gammopathy. The gammopathies included all major immunoglobulin isotypes. Chemotherapeutic intervention in 2 cases precipitated the emergence of new clones within a matter of weeks. Further investigation of oligo-/monoclonal gammopathies in these patients may lead to a clearer understanding of the clinical course and provide further insight into the underlying mechanisms of B-cell abnormalities in ataxia-telangiectasia.


Assuntos
Ataxia Telangiectasia/complicações , Hipergamaglobulinemia/etiologia , Paraproteinemias/etiologia , Adolescente , Proteínas Sanguíneas/análise , Criança , Pré-Escolar , Doenças em Gêmeos , Feminino , Humanos , Hipergamaglobulinemia/sangue , Isotipos de Imunoglobulinas/sangue , Masculino , Neoplasias/complicações , Paraproteinemias/sangue , Paraproteinemias/genética , Paraproteinemias/patologia , Subpopulações de Linfócitos T/patologia
3.
J Immunol ; 162(11): 6401-9, 1999 Jun 01.
Artigo em Inglês | MEDLINE | ID: mdl-10352253

RESUMO

Engagement of TCR by its ligand, the MHC/peptide complex, causes T cell activation. T cells respond positively to stimulation with agonists, and are inhibited by antagonist MHC/peptide ligands. Failure to induce proper conformational changes in the TCR or fast TCR/MHC dissociation are the leading models proposed to explain anergy induction by antagonist ligands. In this study, we demonstrate that presentation of between 1 and 10 complexes of agonist/MHC II by unfixed APC induces T cell anergy that persists up to 7 days and has characteristics similar to anergy induced by antagonist ligand or TCR occupancy without costimulation. Furthermore, anergy-inducing doses of hemagglutinin 306-318 peptide led to the engagement of less than 1000 TCR/CD3 complexes. Thus, engagement of a subthreshold number of TCR by either a low density of agonist/MHC or a 2-3 orders of magnitude higher density of antagonist/MHC causes anergy. Moreover, we show that anergy induced by low agonist concentrations is inhibited in the presence of IL-2 or cyclosporin A, suggesting involvement of the calcineurin signaling pathway.


Assuntos
Anergia Clonal/imunologia , Receptores de Antígenos de Linfócitos T/agonistas , Receptores de Antígenos de Linfócitos T/metabolismo , Linfócitos T/imunologia , Linfócitos T/metabolismo , Anergia Clonal/efeitos dos fármacos , Células Clonais , Ciclosporina/farmacologia , Citocinas/biossíntese , Relação Dose-Resposta Imunológica , Regulação para Baixo/imunologia , Antígeno HLA-DR1/análise , Glicoproteínas de Hemaglutininação de Vírus da Influenza , Hemaglutininas Virais/análise , Hemaglutininas Virais/imunologia , Hemaglutininas Virais/farmacologia , Humanos , Imunossupressores/farmacologia , Interleucina-2/farmacologia , Ligantes , Ativação Linfocitária/efeitos dos fármacos , Ativação Linfocitária/imunologia , Substâncias Macromoleculares , Orthomyxoviridae/imunologia , Fragmentos de Peptídeos/análise , Fragmentos de Peptídeos/imunologia , Fragmentos de Peptídeos/farmacologia , Receptores de Antígenos de Linfócitos T/antagonistas & inibidores , Receptores de Antígenos de Linfócitos T/biossíntese , Receptores de Interleucina-2/biossíntese , Linfócitos T/química , Fatores de Tempo , Regulação para Cima/imunologia
4.
J Biol Chem ; 271(13): 7297-300, 1996 Mar 29.
Artigo em Inglês | MEDLINE | ID: mdl-8631746

RESUMO

In contrast to excitable tissues where calcium channels are well characterized, the nature of the B lymphocyte calcium channel is unresolved. Here, we demonstrate by single cell analysis of freshly isolated rat B cells that the anti-immunoglobulin (Ig)-induced calcium influx takes place through a channel which shares pharmacologic and serologic properties with the L-type calcium channel found in excitable tissues. It is sensitive to the dihydropyridines nicardipine and Bay K 8644, to calciseptine, and to an anti-peptide antibody raised against the alpha1 subunit of the L-type calcium channel, but is voltage-insensitive. Anti-alpha1 and anti-alpha2 antibodies stain B but not T lymphocytes. Application of a cGMP agonist, measurement of cGMP levels in anti-Ig-stimulated B cells, and examining the effect of a guanylyl cyclase inhibitor on the anti-Ig response show that cGMP mediates the influx. This possibly involves a cGMP-dependent protein kinase. The anti-Ig-induced response is not abolished by prior treatment of B cells with a high dose of thapsigargin. These findings undermine the widely held belief of a categorical divide between excitable and non-excitable tissue calcium channels, demonstrate the limitations of the capacitative calcium influx theory, and point to a distinction between the calcium response mechanisms utilized by B and T lymphocytes.


Assuntos
8-Bromo Monofosfato de Adenosina Cíclica/farmacologia , Anticorpos/farmacologia , Linfócitos B/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Canais de Cálcio/fisiologia , Cálcio/metabolismo , GMP Cíclico/metabolismo , Éster Metílico do Ácido 3-Piridinacarboxílico, 1,4-Di-Hidro-2,6-Dimetil-5-Nitro-4-(2-(Trifluormetil)fenil)/farmacologia , Animais , Linfócitos B/citologia , Linfócitos B/efeitos dos fármacos , Canais de Cálcio/efeitos dos fármacos , Canais de Cálcio/imunologia , Canais de Cálcio Tipo L , Membrana Celular/efeitos dos fármacos , Membrana Celular/metabolismo , Separação Celular , Células Cultivadas , Proteínas Quinases Dependentes de GMP Cíclico/metabolismo , Ácido Egtázico/farmacologia , Venenos Elapídicos/farmacologia , Imunoglobulina D/farmacologia , Imunoglobulina M/farmacologia , Cinética , Linfonodos/citologia , Linfonodos/imunologia , Nicardipino/farmacologia , Ratos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...